Elan names Robert Ingram as new chairman
pharmafile | December 10, 2010 | Appointment | Research and Development, Sales and Marketing |Â Â Elan, appointment, research and development, sales and marketingÂ
Elan has appointed former Glaxo Wellcome chief executive Robert Ingram as its chairman-designate.
Ingram led Glaxo between 1997 and 2000 and, after its merger with SmithKline Beecham, served in a number of roles at GSK, including vice chairman of pharmaceuticals.
He will assume his new role at Elan on 26 January 2011, succeeding Kyran McLaughlin.
Commenting on his appointment Robert said: “Elan is a company with tremendous science, talent and potential to have a positive impact on millions of patient lives and their families.
“I am impressed with the progress the company has made over the past several years in advancing the science, improving its financial performance, and constructing unique and far reaching collaborations which will enable the company to continue to invest in science and innovate within the world of novel therapeutic advances. I look forward to working with the board and the management team to deliver long term benefits to science, patients and shareholders.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






